Lenvatinib-d4 is a deuterium-labeled version of Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating potent antitumor activities. Stable heavy isotopes like deuterium are incorporated into drug molecules, primarily as tracers for quantitation during drug development. Deuteration can also impact the pharmacokinetic and metabolic profiles of drugs.
- Used as a tracer.
- Used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
- Inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET.